PDCD1 and melanoma: Lifileucel’s definitive clinical trial (NCT02360579) is an open-label, multi-cohort, multi-center Phase 2 clinical trial in patients with advanced melanoma who have progressed on or after PD-1/PD-L1 inhibitors.